Oral semaglutide helps adults with obesity lose fat and keep muscle strength in real-world use
In 70 adults with obesity but no diabetes, 4 months of oral semaglutide cut 5.4 kg, mostly fat, while muscle strength held steady.
Summary
Oral semaglutide is approved for type 2 diabetes, but real-world data on its use for obesity are scarce. This Spanish multicenter, prospective observational study followed 70 adults with obesity and no diabetes who started the drug as part of routine care. After 4 months, average body weight fell by 5.4 kg, mostly from fat mass. Waist circumference and visceral fat also decreased. Lean mass dropped slightly, but muscle strength did not change. About 44% of participants reached clinically meaningful weight loss. Metabolic markers, inflammatory markers, and depressive symptoms also improved. Because there was no comparison group and follow-up was short, the findings show an association rather than proof of cause. They suggest oral semaglutide at diabetes-approved doses may be a useful option for some people with obesity.
Detailed Summary
Obesity is a chronic, adiposity-based disease, and lifestyle changes alone often produce limited long-term results. Injectable GLP-1 therapies have drawn attention, but oral semaglutide is currently approved only for type 2 diabetes, and little real-world evidence exists on its use in obesity. Whether weight loss preserves muscle is also a key concern for healthy aging.
This multicenter, prospective, observational study enrolled 70 adults with obesity but without diabetes who started oral semaglutide as part of routine clinical care. The researchers assessed body weight, body composition, and muscle strength. Secondary outcomes were metabolic parameters, inflammatory markers, and depressive symptoms.
After 4 months, mean body weight fell by 5.4 kg, mainly from reduced fat mass. Waist circumference and visceral fat also declined. Lean mass dropped slightly, but muscle strength remained unchanged. Clinically meaningful weight loss was reached by 44.3% of participants. The authors also report improvements in metabolic parameters, inflammatory markers, and depressive symptoms, though the abstract does not give specific values.
The results suggest that oral semaglutide at doses approved for type 2 diabetes may produce short-term weight loss in people with obesity, driven largely by fat loss with preserved strength. This could appeal to patients who prefer a non-injectable option. The visceral fat and inflammatory changes are relevant to cardiometabolic and longevity-related health.
Several caveats apply. There was no comparator group, so changes cannot be attributed solely to the drug. The sample was small, follow-up was only 4 months, and the abstract gives no detail on dropout, side effects, or exact doses. Longer, controlled studies are needed to confirm durability and the effect on lean mass.
Key Findings
- Mean body weight fell 5.4 kg after 4 months of oral semaglutide in 70 adults with obesity without diabetes.
- Weight loss came mainly from fat mass, with reductions in waist circumference and visceral fat.
- Lean mass declined slightly, but muscle strength remained unchanged.
- 44.3% of patients achieved clinically meaningful weight loss.
- Metabolic parameters, inflammatory markers, and depressive symptoms improved, per the authors.
Methodology
This was a multicenter, prospective, observational study of 70 adults with obesity and no diabetes who began oral semaglutide in routine care. Body weight, body composition, muscle strength, metabolic and inflammatory markers, and depressive symptoms were assessed over 4 months. There was no control group.
Study Limitations
The lack of a comparator group, small sample, and 4-month follow-up limit causal inference and say nothing about long-term durability. The abstract lacks detail on doses, adverse events, dropouts, and the size of metabolic, inflammatory, and mood changes. Real-world observational designs are also prone to selection bias and confounding by concurrent lifestyle changes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: